{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-036381","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.164613+00:00","generated_at":"2026-05-31T04:28:46.071886+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"GT Biopharma repositions Dr. Miller as Consulting Senior Medical Director for conflict-of-interest compliance","bullets":["Dr. Jeffrey Miller ceased as Consulting Chief Medical Officer and Consulting Chief Scientific Officer effective September 16, 2024.","He commenced as Consulting Senior Medical Director to align with University of Minnesota conflict-of-interest policies.","The change precedes the Phase I clinical trial of GTB-3650 compound at the University of Minnesota."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-036381","json":"https://secwatch.observer/filing/0001493152-24-036381.json","markdown":"https://secwatch.observer/filing/0001493152-24-036381.md","text":"https://secwatch.observer/filing/0001493152-24-036381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/0001493152-24-036381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:28:46.071886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a040dfd356","claim":"Dr. Jeffrey Miller changed role as Consulting Senior Medical Director at GT Biopharma, Inc..","evidence_excerpt":"Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced service as the Registrant’s Consulting Senior Medical Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/0001493152-24-036381-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving as Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced as Consulting Senior Medical Director"},{"label":"Role","value":"Consulting Senior Medical Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}